{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:26:26Z","timestamp":1779200786023,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejca.2022.04.020","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:54:35Z","timestamp":1653008075000},"page":"106-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions"],"prefix":"10.1016","volume":"170","author":[{"given":"Petros","family":"Christopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Kluck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4426-2400","authenticated-orcid":false,"given":"Martina","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"L\u00fcders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Roeper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger-Fei","family":"Falkenstern-Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlen","family":"Szewczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Sticht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4095-8649","authenticated-orcid":false,"given":"Felix C.","family":"Saalfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claas","family":"Wesseler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Hackanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Dintner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-7538","authenticated-orcid":false,"given":"Martin","family":"Faehling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Kuon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Janning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Kauffmann-Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-3281","authenticated-orcid":false,"given":"Daniel","family":"Kazdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-8440","authenticated-orcid":false,"given":"Sylke","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Eichhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8058-8884","authenticated-orcid":false,"given":"Farastuk","family":"Bozorgmehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1543-9281","authenticated-orcid":false,"given":"Rajiv","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Tufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4844-4087","authenticated-orcid":false,"given":"Martin","family":"Wermke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Loges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7039-0791","authenticated-orcid":false,"given":"Wolfgang M.","family":"Brueckl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4861-4517","authenticated-orcid":false,"given":"Christian","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Misch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7452-7129","authenticated-orcid":false,"given":"Nikolaj","family":"Frost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Groh\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Liern","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huamao M.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6668-5327","authenticated-orcid":false,"given":"Jan","family":"Budczies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.04.020_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247620","article-title":"Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review","volume":"16","author":"Burnett","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2022.04.020_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.4761","article-title":"Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1\/2 open-label nonrandomized clinical trial","author":"Zhou","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib3","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment","volume":"19","author":"Friedlaender","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib5","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update","volume":"39","author":"Hanna","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib6","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2022.04.020_bib7","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR exon 20 insertions and Co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib8","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.esmoop.2021.100253","article-title":"The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma","volume":"6","author":"Kirchner","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2022.04.020_bib9","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1111\/cas.14156","article-title":"Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer","volume":"110","author":"Matsumoto","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2022.04.020_bib10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2020.08.007","article-title":"Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing","volume":"148","author":"Christopoulos","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2022.04.020_bib11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ijc.32133","article-title":"Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: analysis of the first 3,000 Heidelberg cases","volume":"145","author":"Volckmar","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.04.020_bib12","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/JTO.0000000000000570","article-title":"Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients","volume":"10","author":"K\u00f6nig","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib13","doi-asserted-by":"crossref","first-page":"670483","DOI":"10.3389\/fonc.2021.670483","article-title":"Feasibility and challenges for sequential treatments in ALK-rearranged non-small-cell lung cancer","volume":"11","author":"Elsayed","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib14","doi-asserted-by":"crossref","first-page":"S780","DOI":"10.1016\/S1556-0864(21)01995-X","article-title":"Real-world study of NSCLC with EGFR exon 20 insertions (ELCC 2021 Abstract 153P)","volume":"16","author":"Christopoulos","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib15","doi-asserted-by":"crossref","first-page":"S972","DOI":"10.1016\/j.annonc.2021.08.1829","article-title":"Systematic review and meta-analysis of immunotherapy effectiveness for pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertions (ESMO 2021 congress abstract 1224P)","volume":"32","author":"Christopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib16","article-title":"Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma","author":"Budczies","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2022.04.020_bib17","doi-asserted-by":"crossref","first-page":"1860586","DOI":"10.1080\/2162402X.2020.1860586","article-title":"A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma","volume":"10","author":"Budczies","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejca.2022.04.020_bib18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","article-title":"Gene expression markers of tumor infiltrating leukocytes","volume":"5","author":"Danaher","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.04.020_bib19","first-page":"100051","article-title":"EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors","volume":"1","author":"Vasconcelos","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.ejca.2022.04.020_bib20","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/j.cllc.2019.06.018","article-title":"Effectiveness of treatments for advanced non-small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations","volume":"20","author":"Wu","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2022.04.020_bib21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.lungcan.2020.03.014","article-title":"EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study","volume":"145","author":"Yang","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2022.04.020_bib22","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1016\/j.cllc.2021.04.009","article-title":"EGFR exon 20 insertion mutations: clinicopathological characteristics and treatment outcomes in advanced non-small cell lung cancer","volume":"22","author":"Leal","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejca.2022.04.020_bib23","doi-asserted-by":"crossref","first-page":"9098","DOI":"10.1200\/JCO.2021.39.15_suppl.9098","article-title":"Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations","volume":"39","author":"Ou","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib24","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1016\/j.jtho.2021.06.025","article-title":"Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations","volume":"16","author":"Saalfeld","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib25","doi-asserted-by":"crossref","first-page":"S892","DOI":"10.1016\/j.annonc.2020.08.1726","article-title":"1412TiP Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)","volume":"31","author":"J\u00e4nne","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib26","doi-asserted-by":"crossref","first-page":"S873","DOI":"10.1016\/j.jtho.2021.08.082","article-title":"OA15.01 mobocertinib in EGFR exon 20 insertion\u2013positive metastatic NSCLC patients with disease control on prior EGFR TKI therapy","volume":"16","author":"Spira","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib27","doi-asserted-by":"crossref","first-page":"S964","DOI":"10.1016\/j.annonc.2021.08.1816","article-title":"1211P Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion","volume":"32","author":"Ou","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib28","doi-asserted-by":"crossref","first-page":"9052","DOI":"10.1200\/JCO.2021.39.15_suppl.9052","article-title":"Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy","volume":"39","author":"Minchom","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib29","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","article-title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","volume":"29","author":"Kron","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ijc.31893","article-title":"Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma","volume":"144","author":"Christopoulos","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.04.020_bib31","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.18632\/oncotarget.26886","article-title":"Defining molecular risk in ALK+ NSCLC","volume":"10","author":"Christopoulos","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2022.04.020_bib32","doi-asserted-by":"crossref","first-page":"S928","DOI":"10.1016\/j.jtho.2021.08.182","article-title":"MA14.01 distribution and detectability of EGFR exon 20 insertion variants in non\u2013small cell lung cancer","volume":"16","author":"Ou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jtho.2015.12.103","article-title":"Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs","volume":"11","author":"Lin","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib34","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.jtho.2021.01.283","article-title":"OA04.03 mobocertinib in NSCLC with EGFR exon 20 insertions: results from EXCLAIM and pooled platinum-pretreated patient populations","volume":"16","author":"Zhou","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2022.04.020_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2022.01.014","article-title":"Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer","volume":"166","author":"Huang","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2022.04.020_bib36","doi-asserted-by":"crossref","first-page":"S1989","DOI":"10.21037\/jtd.2018.05.61","article-title":"EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC","volume":"10","author":"Christopoulos","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejca.2022.04.020_bib37","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.21873\/anticanres.15196","article-title":"Prognostic relevance of the relative presence of CD4, CD8 and CD20 expressing tumor infiltrating lymphocytes in operable non-small cell lung cancer patients","volume":"41","author":"Giatromanolaki","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2022.04.020_bib38","doi-asserted-by":"crossref","first-page":"13116","DOI":"10.18632\/oncotarget.14471","article-title":"Th1 high in tumor microenvironment is an indicator of poor prognosis for patients with NSCLC","volume":"8","author":"Huang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2022.04.020_bib39","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1158\/0008-5472.CAN-08-3479","article-title":"IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation","volume":"69","author":"Xiao","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.04.020_bib40","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/eji.201444497","article-title":"IFN-\u03b3 regulates survival and function of tumor-induced CD11b+ Gr-1high myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1","volume":"44","author":"Medina-Echeverz","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ejca.2022.04.020_bib41","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1067\/msy.2002.119795","article-title":"Clinical significance of serum TH1\/TH2 cytokines in patients with pulmonary adenocarcinoma","volume":"131","author":"Yamazaki","year":"2002","journal-title":"Surgery"},{"key":"10.1016\/j.ejca.2022.04.020_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/1758835921996509","article-title":"Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer","volume":"13","author":"Magios","year":"2021","journal-title":"Ther Adv Med Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:56Z","timestamp":1760733416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922002301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":42,"alternative-id":["S0959804922002301"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}